Elrayess, Fadya

Elrayess, Fadya was paid $563K by Medicaid between Jan 2018 and Dec 2024, across 12 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 89% of everything it billed.

33Billing provider infoELRAYESS, FADYA
PAWTUCKET, RI 02860

33aNPI1285746925assigned 08/31/2006

33bProvider typeFamily Medicine Physician

28Total paid$563K

24GClaims4,065

24DCodes billed12

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Family Medicine Physician providers in Rhode Island

Rank by total paid#16 of 220

Median peer was paid$33K

This provider vs. median17×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	609	$82K
2019	726	$112K
2020	625	$77K
2021	716	$83K
2022	683	$78K
2023	418	$76K
2024incomplete	288	$56K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	89%	2,871	2,668	$499K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	6.2%	666	629	$35K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	1.7%	204	193	$10K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	1.1%	78	78	$6K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	68	64	$6K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	46	46	$3K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	54	50	$2K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	12	12	$1K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	29	27	$782.32
80048	Basic metabolic panel (calcium, ionized)	<1%	13	13	$530.41
83036	Hemoglobin; glycosylated (A1C)	<1%	12	12	$518.51
3078F		<1%	12	12	$0.12

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.